
News|Articles|September 3, 2025
6 Nephrology Headlines You Missed in August 2025
Author(s)Abigail Brooks, MA
Fact checked by: Ryan Livingston
Check out renal FDA news and new research on pediatric kidney stone management, CKD trends, spironolactone for dialysis patients, and more.
Advertisement
Advertisement
August 2025 delivered a wave of important updates in nephrology, spanning new US Food and Drug Administration (FDA) approvals, clinical trial readouts, and global public health insights. The FDA cleared 2 generic versions of iron sucrose injection for iron deficiency anemia in
Related to this article

Suceena Alexander, MD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to discuss platform trial design in IgA nephropathy and beyond.

Hiddo Heerspink, PharmD, PhD, joins Brendon Neuen, MBBS, PhD, and Shikha Wadhwani, MD, MS, to unpack finerenone’s FIND-CKD data in FSGS.

Lesley Inker, MD, MS, joins Brendon Neuen, MBBS, PhD, to unpack GFR slope and hierarchical composite endpoints in glomerular disease trials.

Approval of obinutuzumab for adults with PMN follows MAJESTY, where 37% vs 6% achieved complete remission at week 104 vs tacrolimus.

Children receiving 50 nmol PVX108 increased their tolerated peanut dose 2.4-fold, with no treatment-related anaphylaxis in the phase 2 trial.

Ackerman and Bunick review 52-week AMETHYST data for litifilimab in refractory cutaneous lupus and make the case for dermatology-led CLE care.

Lawrence Eichenfield, MD, discusses phase 2 nemolizumab data in children aged 2 - 11 with atopic dermatitis, from caregiver-rated itch to sleep gains.
Advertisement
Advertisement

